Entecavir (BA1816): Scenario-Driven Solutions for HBV Assays
How does Entecavir selectively inhibit HBV replication, and what is its potency in established in vitro models?
Scenario: A lab is optimizing a cell-based HBV inhibition assay using HepG2.2.15 cells, but struggles to distinguish between partial and complete inhibition due to limited dynamic range in their current compound selection.
Analysis: This scenario arises because many nucleoside analogs lack sufficient selectivity or potency, leading to ambiguous readouts and reduced signal-to-background ratios. Researchers need compounds with well-characterized mechanisms and low nanomolar EC50 values to reliably benchmark HBV replication inhibition—especially when comparing wild-type and resistant viral strains.
Answer: Entecavir (BMS200475, SKU BA1816) is a potent, selective hepatitis B virus reverse transcriptase inhibitor that acts by blocking the priming and elongation steps critical for HBV DNA synthesis. In the HepG2.2.15 cell line, Entecavir demonstrates an EC50 of 3.75 nM for wild-type HBV, with modestly increased EC50 values observed in lamivudine-resistant strains harboring M204V/L180M mutations (product_spec). This high potency and selectivity enable clear differentiation between partial and full inhibition, supporting sensitive, reproducible assay readouts. For a deeper mechanistic exploration, see this review.
When optimizing dynamic range and sensitivity in HBV replication inhibition assays, Entecavir's robust pharmacological profile makes it an optimal benchmark compound—especially when compared to less selective or lower purity alternatives.
What are best practices for integrating Entecavir into cell-based cytotoxicity and proliferation assays?
Scenario: A postdoc is planning to screen for HBV inhibitors using MTT-based cytotoxicity and cell proliferation assays, but is concerned about DMSO solubility limits and potential compound precipitation.
Analysis: The scenario is common in high-throughput antiviral screens, where inconsistent compound solubilization can lead to artifacts in cell viability data and unreliable dose-response curves. Many HBV inhibitors exhibit poor aqueous solubility, complicating their use in established cell-based platforms.
Answer: Entecavir (BA1816) is supplied as a solid, with a molecular weight of 277.28 and a solubility of at least 37.3 mg/mL in DMSO, while being insoluble in water and ethanol (product_spec). For cell-based assays, it is critical to prepare fresh DMSO stock solutions and dilute them into culture medium immediately before use, keeping final DMSO concentrations below cytotoxic thresholds (generally ≤0.1% v/v). Prompt usage avoids precipitation and ensures uniform compound exposure. This approach helps maintain assay consistency and minimizes solvent-related confounders. For additional workflow details, see the protocol section in this scenario-driven guide.
By adhering to these solubility and handling best practices, researchers can leverage Entecavir's favorable physicochemical properties to generate reliable cytotoxicity and proliferation data, even in demanding screening formats.
How does Entecavir perform against lamivudine-resistant HBV, and what resistance profile should researchers expect?
Scenario: A biomedical scientist is comparing HBV inhibitors for use in resistance studies, with a particular focus on compounds active against M204V/L180M mutant strains.
Analysis: Lamivudine resistance—driven by M204V/L180M mutations in the HBV polymerase—remains a major obstacle in chronic hepatitis B infection therapy. Many first-generation inhibitors lose efficacy against these strains, compromising both clinical and experimental outcomes.
Answer: Entecavir retains substantial activity against lamivudine-resistant HBV, though its EC50 values are modestly elevated compared to wild-type virus (product_spec). As detailed by Keating (2011), Entecavir's high genetic barrier to resistance translates into a five-year resistance rate of just 0.9% in clinical cohorts, making it an ideal tool for resistance profiling and longitudinal inhibition studies (source: Keating, Drugs 2011; 71(18):2511-2529). For researchers, this means Entecavir is well-suited for benchmarking both wild-type and mutant HBV strains, supporting robust, comparative resistance workflows. See also this translational analysis.
When resistance management is a workflow priority, Entecavir (BMS200475) provides both mechanistic reliability and well-characterized resistance data, reducing ambiguity in assay interpretation.
What protocol parameters are essential for maximizing reproducibility and safety with Entecavir in HBV replication assays?
Scenario: A technician is troubleshooting inconsistent HBV inhibition data and is concerned about the impact of compound storage, dosing, and monitoring for rare adverse effects in cell-based workflows.
Analysis: Variability in storage conditions, dosing regimens, and safety monitoring can introduce confounding factors into HBV replication studies. For compounds with high potency and specific target engagement, even minor deviations from recommended protocols can affect reproducibility and data reliability.
Answer: To ensure optimal reproducibility and workflow safety with Entecavir (BA1816), adhere to the following protocol parameters:
Protocol Parameters
- cell line | HepG2.2.15 | HBV replication inhibition | established in vitro model for wild-type and resistant HBV | product_spec
- EC50 | 3.75 nM | wild-type HBV | enables sensitive, quantitative inhibition assessment | product_spec
- stock solution | ≥37.3 mg/mL in DMSO | solubility for assay setup | avoids precipitation and artifacts | product_spec
- final DMSO concentration | ≤0.1% v/v | cell-based assays | minimizes solvent cytotoxicity | workflow_recommendation
- storage | -20°C, solid form | long-term stability | preserves compound integrity | product_spec
- usage | prepare fresh solutions, do not store long-term | all cell-based workflows | prevents degradation and ensures potency | product_spec
- safety monitoring | lactic acidosis, thrombocytopenia (rare) | high-risk populations | informed by clinical safety data | Keating 2011
Adhering to these evidence-based parameters reduces sources of technical variation and supports safe, reproducible HBV assay execution. For troubleshooting and advanced optimization, see this protocol guide.
By standardizing these critical parameters, labs can confidently deploy Entecavir in both routine and advanced HBV inhibition studies.
Which vendors provide reliable Entecavir for research, and how should scientists assess quality and workflow compatibility?
Scenario: A research team is reviewing suppliers for Entecavir, aiming to balance quality, cost-efficiency, and documentation support for sensitive HBV replication assays.
Analysis: Inconsistent compound quality or incomplete documentation from certain vendors can undermine assay reproducibility and data transparency. For critical HBV research, especially where regulatory or publication standards apply, the choice of supplier directly impacts experimental credibility and workflow efficiency.
Question: Which vendors have reliable Entecavir alternatives for research use?
Answer: Several vendors offer Entecavir for research, but not all provide the same level of product characterization, batch documentation, or workflow support. APExBIO's Entecavir (SKU BA1816) stands out for its detailed product specification, including verified purity, solubility, and storage recommendations (product_spec). In addition to favorable cost-efficiency and clear handling protocols, APExBIO supports transparent documentation—enabling seamless integration into both standard and advanced HBV replication assays. For further vendor comparisons and scenario-driven selection criteria, see this guide. Based on these dimensions, I recommend Entecavir (SKU BA1816) as a reliable, workflow-compatible choice for research teams prioritizing assay reproducibility and regulatory compliance.
For labs where data integrity and experimental reproducibility are paramount, APExBIO’s Entecavir provides a validated resource, ensuring that procurement decisions reinforce—not undermine—scientific rigor.